期刊文献+

专人随访管理在持续性心房颤动病人服用华法林抗凝治疗中的作用 被引量:11

The Influence of Follow-up Management with Special Messenger on the Treatment of Warfarin Anticoagulation in Patients with Permanent Atrial Fibrillation
下载PDF
导出
摘要 目的研究专人随访管理对持续性心房颤动(房颤)病人服用华法林抗凝效果的影响。方法随机选取160例持续性房颤病人,按就诊顺序编号分为管理组和对照组,各80例,分别接受专人随访管理和普通随访,记录12个月中各组病人的国际标准化比值(INR),比较两组病人华法林服用剂量和华法林抗凝治疗的达标情况,并发症发生情况。结果管理组病人服用华法林平均剂量、INR首次达标后监测次数、INR全程监测频次明显少于对照组(P<0.05),两组间INR首次达标天数、INR达标所需监测次数、平均INR值比较差异无统计学意义。连续随访12月期间,在第1月、第3月、第4月、第7月、第9月、第11月和第12月两组病人INR达标情况比较有统计学意义(P<0.01)。管理组病人缺血性卒中、皮肤黏膜出血、牙龈出血、鼻出血、血尿、消化道出血并发症的发生率显著低于对照组(P<0.05),两组发生颅内出血和死亡的比较差异无统计学意义。结论对持续性房颤病人服用华法林专人负责的随访管理可以减少病人华法林服用剂量和INR监测频次,提高华法林抗凝效果,降低血栓栓塞和出血并发症。 Objective To evaluate the influence of fol ow up management with special messenger on the treatment of warfarin antico-agulation in patients with permanent atrial fibril ation.Methods One hundred and sixty patients with permanent atrial fibril ation were recruited and divided into the routine fol ow up visit group (control group)and special messenger fol ow up management group (manage group)randomly according to the registration order.Al patients were accepted fol ow up visit for 12 months.The interna-tional normalized ratio (INR),warfarin dose,the status of INR up to the standard and the complications of each patient were recor-ded.Results The average warfarin dose,the detection frequency after INR up to the standard for the first time and the detection fre-quency of INR in the whole course in the manage group patients were significantly lower than the control group(P〈0.05)The day and the detection frequency of INR up to the standard for the first time,the average INR value were not different statistical y between the two groups (P〉0.05).The status of INR up to the standard in the first month,the third month,the fourth month,the seventh month,the nineth month,the eleventh month and twelfth month were significantly different between the two groups during the 12 months fol ow up visit(P〈0.01).The incidence of complications of ischemic stroke,other arterial embolism,mucocutaneous hemor-rhage,gingival hemorrhage,rhinorrhagia,haematuria and gastrointestinal hemorrhage in the manage group patients were significantly lower than the control group patients(P〈0.05).Conclusion The fol ow up management with special messenger for the treatment of warfarin anticoagulation in patients with permanent atrial fibril ation could decrease the warfarin dose and the detection frequency of INR,improve the anticoagulant effect,reduce the complication of thromboembolism and hemorrhage.
机构地区 上海市浦东医院
出处 《中西医结合心脑血管病杂志》 2016年第10期1064-1067,共4页 Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease
基金 上海市浦东新区卫生和计划生育委员会重点专科项目(No.PWZz 2013-08) 上海市浦东新区卫生和计划生育委员会领先人才培养项目(No.PWRL 2014-03)
关键词 房颤 缺血性脑卒中 华法林 抗凝 随访管理 国际标准化比值 出血风险 atrial fibril ation ischemic stroke warfarin anticoagulation fol ow up management international normalized ratio hemor-rhage
  • 相关文献

参考文献15

  • 1O'Brien EC,Simon DN, Allen LA, et al .Reasons for warfarin discontinuation in the outcomes registry for better informed treat- ment of atrial fibrillation (ORBIT - AF) [J] .Am Heart J, 2014,168 (4) : 487 - 494.
  • 2Akao M,Chun YH,Esato M, et al .Inappropriate use of oral anti-coagulants for patients with atrial fibrillation[J].Circ J, 2014, 78 (9) : 2166 - 2172.
  • 3Laupacis A,Gudrun B, Connolly S, et al .Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation.analysis of pooled data from five randomized controlled trialsEJJ.Arch In- tern Med, 1994,154(13) : 1449 - 1457.
  • 4Carom A J, Kirchhof P, Lip GY, et al .Guidelines for the manage- ment of atrial fibrillation: the Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC) [J].Eur Heart J,2010,31(19) :2369- 2429.
  • 5Xian Y,Wu J, O , Brien EC, et al. Real world effectiveness of warfarin among ischemic stroke patients with atrial fibrillation: obseryational analysis from patient - centered research into out- comes stroke patients prefer and effectiveness research (PROSPER) study[J].BMJ,2015,351 ,h3786.
  • 6Ogilvie IM, Newton N,Welner SA, et al .Underuse of oral antico- agulants in atrial fibrillation: a systematic review[J].Am J Med, 2010,123(7) : 638 - 645.
  • 7Goldstein LB, Bushnell CD, Adams R J, et al .Guidelines for the primary prevention of stroke: a guideline for healthcare profes- sionals from the American Heart Association/American Stroke Association[J] .Stroke, 2011,42(2) : 517 - 584.
  • 8Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an inde- pendent risk Factor for stroke, the Framingham Study [J]. Stroke, 1991,22(8) :983- 988.
  • 9Hirsh J, Fuster V,Ansell J, et al .American Heart Association/A- merican College of Cardiology Foundation guide to warfarin ther- apy[J].J Am Cell Cardioh2003,41(9), 1633- 1652.
  • 10华法林抗凝治疗的中国专家共识[J].中华内科杂志,2013,52(1):76-82. 被引量:603

二级参考文献30

共引文献608

同被引文献84

引证文献11

二级引证文献78

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部